Here's How Acadia Pharmaceuticals Crushed It in 2017
About 1 million patients in the U.S. suffer from Parkinson's disease. Unfortunately, nearly 40% of them will experience hallucinations and delusions in their daily life, which is a disease state called Parkinson's disease psychosis (PDP).
Caring for a patient who suffers from Parkinson's disease is hard, but adding PDP to the mix elevates their needs to a whole new level. Given the challenge, many patients who develop PDP are sent off to a nursing home.
For decades, there wasn't much that providers could do to treat PDP. However, Acadia Pharmaceuticals (NASDAQ: ACAD) changed all of that in 2016 when the Food and Drug Administration approved its PDP drug Nuplazid for sale. Given the enormous unmet medical need and lack of competition, Acadia had a wide-open market opportunity ahead of it -- if it could successfully execute against its commercialization plan.
Source: Fool.com
Acadia Pharmaceuticals Aktie
Einseitige Meinung: Acadia Pharmaceuticals erhält nur Buy-Einschätzungen und keine Sell-Einschätzungen.
Ein positives, wenn auch nicht starkes, Potenzial für Acadia Pharmaceuticals mit einem Kursziel von 29 € im Vergleich zu 24.33 €.
